Cas:61714-25-8 w-5 hydrochloride manufacturer & supplier

Chemical Name:w-5 hydrochloride

CAS.NO:61714-25-8

Synonyms:N-(6-Aminohexyl)-1-naphthalenesulfonamide hydrochloride (1:1);N-(6-aminohexyl)naphthalene-1-sulfonamide hydrochloride;1-NaphthalenesulfonaMide,N-(6-aMinohexyl)-,Monohydrochloride;1-Naphthalenesulfonamide,N-(6-aminohexyl)-,monohydrochlorde;1-Naphthalenesulfonamide, N-(6-aminohexyl)-, hydrochloride (1:1);N-(6-Aminohexyl)-1-naphthalenesulfonamide, hydrochloride (1:1);N-(6-Aminohexyl)naphthalene-1-sulfonamide hydrochloride (1:1);N-(6-AMINOHEXYL)-1-NAPHTHALENESULFONAMIDE HCL;1-Naphthalenesulfonamide, N-(6-aminohexyl)-, monohydrochlorde;L66J BSWM6Z &&HCl;AMINOHEXYL NAPHTHALENE-1-SULPHONAMIDE HYDROCHLORIDE;N-(6-AMINOHEXYL)-1-NAPHTHALENESULPHONAMIDE HYDROCHLORIDE;N-(6-Aminohexyl)-1-naphthalenesulfonamide monohydrochlorde;Cirazoline hydrochloride;W-5;N-(6-AMINOHEXYL)-1-NAPHTHALENESULFONAMIDE HYDROCHLORIDE

Molecular Formula:C₁₆H₂₃ClN₂O₂S

Molecular Weight:342.884

HS Code:

Physical and Chemical Properties:

Melting point:150-152ºC

Boiling point:493.2ºC at 760mmHg

Density:1.176g/cm3

Index of Refraction:

PSA:80.57000

Exact Mass:342.116882

LogP:5.61120

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like N-(6-Aminohexyl)-1-naphthalenesulfonamide hydrochloride (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(6-AMINOHEXYL)-1-NAPHTHALENESULFONAMIDE HYDROCHLORIDE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,L66J BSWM6Z &amp Use and application,W-5 technical grade,usp/ep/jp grade.

Related News: The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. w-5 hydrochloride manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). w-5 hydrochloride supplier From the perspective of product structure, the varieties of these enterprises are mainly concentrated in vitamins, antipyretics and analgesics, antibiotics and corticosteroids (ie bulk drug substances). w-5 hydrochloride vendor The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. w-5 hydrochloride factory Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).